Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This investigation is a prospective, open-label pharmacokinetic study of daptomycin
prophylaxis in patients undergoing coronary artery bypass graft surgery without valvular
replacement.
Phase:
Phase 3
Details
Lead Sponsor:
Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Collaborators:
Cubist Pharmaceuticals LLC Hartford Hospital Western University of Health Sciences